Madhulika Eluri
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Case Western University School of Medicine, Cleveland, Ohio, US, Doctor of Medicine |
| 2012 | University of North Carolina, Chapel Hill, North Carolina, US, Biology and Sociology, Bachelor of Science |
Postgraduate Training
| 2020-2023 | Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2020 | Clinical Residency, Internal Medicine, Duke University Hospital, Durham, North Carolina |
Licenses & Certifications
| 2023 | Medical Oncology Board Certification |
| 2020 | American Board of Internal Medicine (ABIM) |
Honors & Awards
| 2023 | Conquer Cancer, Endowed Women Who Conquer Cancer Young Investigator |
| 2023 | MD Anderson Chief Fellow, The University of Texas MD Anderson Cancer Center |
| 2022 - 2023 | ASCO Gastrointestinal Symposium Merit Award, ASCO |
| 2022 - 2023 | ASCO/FDA Fellow’s Day Workshop, ASCO |
| 2022 - 2023 | FDA-AACR Oncology Educational Fellowship, AACR |
| 2022 | ASCO/AACR Methods in Clinical Cancer Research Workshop, ASCO/AACR |
| 2022 | Nannete Holmes-Abrams and Bruce Abrams Colorectal Cancer Fellowship, Nannete Holmes-Abrams and Bruce Abrams Colorectal Cancer |
| 2018 - 2019 | Faculty-Resident Research Grant, Grant, Duke University Hospital |
| 2017 | Graduated with Honors with Distinction in Research, Case Western University School of Medicine |
| 2016 | Medical Student Scholarship, Committee of the Association of Indian Physicians of Northern Ohio |
| 2014 | National Injury Research Fellow, Center for Injury Research and Policy |
| 2013 - 2017 | Kaiser-Permanente Excellence in Teaching Committee, Case Western Reserve University School of Medicine |
| 2012 | Graduated with Distinction and Highest Honors, University of North Carolina |
| 2010 - 2011 | Kenan-Biddle Partnership $10,000 Grant, Kenan-Biddle Foundation |
| 2010 | Cincinnati Children’s Summer Research Fellowship, Cincinnati Children's Hospital |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. Updates in Hematology/Oncology. Invited. Houston, Texas, US.
National Presentations
- 2024. Chemotherapy in biliary tract cancers – where are we now?. Invited, US.
- 2023. Is it time to move away from chemotherapy?. Invited, US.
International Presentations
- 2023. Novel systemic therapies in biliary tract cancers”. Invited. Jaipur, US.
Formal Peers
- Best of ASCO GI 2022 Review for Hem/Onc Fellows. Houston, Texas, US.
- Best of ASCO GI Abstracts Review 2022. Houston, Texas, US.
- Best of ASCO – Biliary Tract Cancers 2023 Review. Houston, Texas, US.
Selected Publications
Peer-Reviewed Articles
- Grewal, K, Pant, S, Hu, I, Eluri, M, An, AW, Serpas Higbie, V, Huey, RW, Kasab, A, Javle, M, Lee, S. CLO25-099. Journal of the National Comprehensive Cancer Network : JNCCN 23(35), 2025. e-Pub 2025. PMID: 40154395.
- Hu, Z, Pavlick, D, Ross, JS, Lee, SS, Eluri, M, Javle, M. Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39772832.
- Wang, L, Singhal, M, Valderrama, A, Nepal, B, Kamble, S, Eluri, M, Malhotra, U, Siegel, AB, Grabner, M, Swami, S, Javle, M. Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA. Future Oncology 20(34):2625-2636, 2024. e-Pub 2024. PMID: 39155836.
- Hatia RI, Eluri M, Hawk ET, Shalaby A, Karatas E, Shalaby A, Abdelhakeem A, Abdel-Wahab R, Chang P, Rashid A, Jalal PK, Amos CI, Han Y, Armaghany T, Shroff RT, Li D, Javle M, Hassan MM. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 32(10):1338-1347, 2023. e-Pub 2023. PMID: 37540502.
- Eluri M, Spiller HA, Casavant MJ, Chounthirath T, Conner KA, Smith GA. Analgesic-Related Medication Errors Reported to US Poison Control Centers. Pain Med 19(12):2357-2370, 2018. e-Pub 2018. PMID: 29186557.
- Eluri M, Feneran A, Bordeaux JS, Ruben B, Ostrowski S, Bastian BC, Honda K. Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study. JAAD Case Rep 3(2):131-134, 2017. e-Pub 2017. PMID: 28367486.
- Zhang R, Gilbert S, Yao X, Vallance J, Steinbrecher K, Moriggl R, Zhang D, Eluri M, Chen H, Cao H, Shroyer N, Denson L, Han X. Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. Pharmacol Res Perspect 3(2):e00118, 2015. e-Pub 2015. PMID: 26038694.
- Eluri M, Kelly M, Kim S. Understanding the psychosocial barriers facing pediatric patients with inflammatory bowel diseases: a pilot study. Gastroenterology 2013 144(5):S-885, 2013.
Invited Articles
- Eluri M, Kopetz S, Parseghian CM. Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response. Clin Cancer Res 29(2):302-304, 2023. e-Pub 2023. PMID: 36378102.
Review Articles
- Parseghian C, Eluri M, Kopetz S, Raghav K. Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Front Cell Dev Biol 11:1176657, 2023. e-Pub 2023. PMID: 37791069.
- Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 41(3):460-471, 2022. e-Pub 2022. PMID: 36351210.
Abstracts
- Eluri M. Characterization of Analgesics-related Medication Errors Reported to U.S. Poison Control Centers. American Academy of Pediatrics Annual Meeting.
- Eluri M. The association of family history of primary liver cancer with cholangiocarcinoma. ASCO Gastrointestinal Symposium.
- Eluri M. Phase 2 Study of Anti-EGFR Rechallenge Therapy with or without Trametinib in RAS/RAF WT Metastatic Colorectal Cancer. ASCO Annual Conference.
- Eluri M. Patterns and clinical outcomes among patients with biliary tract cancers in a large commercially insured US population. Cholangiocarcinoma Foundation Conference.
- Eluri M. Health Care Resource Utilization (HCRU) and Costs in Biliary Tract Carcinoma Patients (BTC) Treated with Systemic Therapy in the United States (US) (Poster Presentation. ASCO Annual Conference.
- Eluri M. Clinical and mutational profiles of microsatellite instability (MSI-H) in intrahepatic cholangiocarcinoma (iCCA. ASCO Gastrointestinal Symposium.
- Eluri M. Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort. ASCO Annual Meeting.
Patient Reviews
CV information above last modified August 04, 2025